Skip to content

Oruka Therapeutics, Inc. ORKA Other Income (Expense)

Other Income (Expense) at other companies

Eli Lilly logo
Eli LillyLLY
-$65M+72.8%
Amgen logo
AmgenAMGN
$75M-95.1%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$14.92M+68.7%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$53K-35.4%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-$20K-110%
Erasca, Inc. logo
Erasca, Inc.ERAS
$4.47M-4.1%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s other income (expense)?
Oruka Therapeutics, Inc. (ORKA) reported other income (expense) of $4.61M in Q1 2026.
How has Oruka Therapeutics, Inc.'s other income (expense) changed year-over-year?
Oruka Therapeutics, Inc.'s other income (expense) increased by 12.9% year-over-year, from $4.09M to $4.61M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.